Reported Late Sunday, Merus Published Two Abstracts Highlighting Updated Interim Clinical Data From The Ongoing Phase 1/2 Enrgy Trial And Early Access Program Of The Bispecific Antibody Zenocutuzumab In Patients With Neuregulin 1 Fusion Cancer
Portfolio Pulse from Benzinga Newsdesk
Merus has published two abstracts on the European Society for Medical Oncology Congress (ESMO) 2023 website, highlighting updated interim clinical data from the ongoing phase 1/2 eNRGy trial and Early Access Program (EAP) of the bispecific antibody zenocutuzumab in patients with neuregulin 1 fusion cancer. The ESMO Congress 2023 will take place in Madrid, Spain October 20-24, 2023.
October 16, 2023 | 7:32 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Merus has published updated interim clinical data from the ongoing phase 1/2 eNRGy trial and Early Access Program of zenocutuzumab, which could potentially impact the company's stock.
The publication of positive interim clinical data can often lead to increased investor confidence and a potential rise in stock price. However, the final impact will depend on the market's interpretation of the data.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100